REQUEST A DEMO
Total
USD $0.00
Search more companies

Contipro A.S. (Czech Republic)

Main Activities: Chemical Manufacturing | All Other Miscellaneous Chemical Product and Preparation Manufacturing
Secondary Activities: Other Food Manufacturing | Pharmaceutical Preparation Manufacturing | Surgical and Medical Instrument Manufacturing | Other Commercial and Industrial Machinery and Equipment Rental and Leasing | Testing Laboratories
Full name: Contipro A.S. Profile Updated: March 03, 2026
Buy our report for this company USD 29.95 Most recent financial data: 2024 Available in: English Download a sample report

Contipro a.s. is a Czech biotechnology and research-driven manufacturer specializing in hyaluronan technologies and hyaluronic acid production for pharmaceutical, medical device and cosmetic markets. Business segments and products are organized around mutually supporting pillars of active substances, pharmaceutical and healthcare-oriented products, and innovative devices. Core output includes biotechnologically manufactured hyaluronic acid and ultra-pure sodium hyaluronate as active pharmaceutical ingredients, alongside hyaluronan specialities and derivatives for research and advanced applications and novel hyaluronan forms designed for innovative uses. The medical portfolio includes advanced hyaluronic-acid-based medical devices, and veterinary pharmaceuticals and medical devices designed for animal health applications. The consumer and cosmetic-oriented portfolio includes anti-ageing ingredients combining hyaluronic acid, polysaccharides, peptides and related actives for formulations, and nutritional supplements including joint nutrition products marketed under dedicated brands. The company also develops and commercializes devices for nanotechnology, including electrospinning equipment for nanofiber production distributed under dedicated product branding, aligning device development with material science expertise. Geographic scope combines a Czech production and R&D base with international sales and supply to global pharmaceutical, medtech, veterinary and cosmetics customers. Key brands and assets include proprietary hyaluronan production know-how, extensive in-house basic and applied research capacity, patent and industrial design portfolios, laboratory infrastructure, and educational programs used to disseminate technical knowledge and support customer adoption. Strategic focus and positioning emphasize deep scientific specialization in hyaluronic acid, continuous product innovation, high purity and quality manufacturing standards, and sustainable biotechnological production pathways aligned with long-term healthcare and advanced materials trends.

Headquarters
Dolni Dobrouc 401
Dolni Dobrouc; Pardubicky; Postal Code: 56102

Contact Details: Purchase the Contipro A.S. report to view the information.

Basic Information
Total Employees:
Purchase the Contipro A.S. report to view the information.
Registered Capital:
Purchase the Contipro A.S. report to view the information.
Financial Auditors:
Purchase the Contipro A.S. report to view the information.
Incorporation Date:
December 30, 1994
Key Executives
Purchase this report to view the information.
Chairman of the Board of Directors
Purchase this report to view the information.
Member of the Supervisory Board
Ownership Details
Purchase this report to view the information.
100%
Company Performance
Financial values in the chart are available after Contipro A.S. report is purchased.
Looking for more than just a company report?

EMIS company profiles are part of a larger information service which combines company, industry and country data and analysis for over 145 emerging markets.

Request a demo of the EMIS service
Key Financial Highlights
Annual growth percentages for latest two years in local currency CZK. Absolute financial data is included in the purchased report.
Net sales revenue
7.27%
Total operating revenue
5.9%
Operating Profit/Loss (EBIT)
13.59%
EBITDA
12.74%
Net Profit/Loss for the Period
4.41%
Total Assets
10.08%
Total Equity
10.32%
Operating Profit Margin (ROS)
2.09%
Net Profit Margin
-0.93%
Return on Equity (ROE)
-0.76%
Quick Ratio
-1.3%
Cash Ratio
1.01%

Related EMIS Industry Reports

To view more information, Request a demonstration of the EMIS service

Buy this company report
Need ongoing access to company, industry or country information?